Allurion Appoints Ojas A. Buch as Chief Operating Officer

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer.

Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company’s Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably.

With a 25-year track record in the healthcare industry, Ojas is a seasoned executive known for his strategic mindset and adaptable tactics. He brings extensive cross-functional expertise and global experience, having led integrated and matrix organizations at GE Healthcare, St Jude Medical (Abbott), CareFusion (Vyaire), Philips and most recently as President, PENTAX Medical – Americas where he drove transformation with a focus on compliance and customer-centricity.

“We are thrilled to welcome Ojas to Allurion as our Chief Operating Officer,” said Dr. Shantanu Gaur, Allurion’s Founder and CEO. “His extensive industry experience and proven leadership skills will be instrumental as we continue to innovate and scale our business globally, while ensuring we uphold the highest quality standards as a publicly traded company.”

“I am proud to serve Allurion at this exciting stage of its lifecycle and look forward to working with our team to advance Allurion’s vision to transform the lives of individuals through cutting-edge weight loss solutions,” said Mr. Buch.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit